Events And
Presentations

59th Annual Meeting of the European Association for the Study of Diabetes

Oct 03, 2023 at 4:30 PM CEST

Oral Presentation: Phase 2, Randomized, Placebo-controlled Trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in subjects with overweight or obesity: a 24-week interim analysis (Session OP 10, Oral Presentation 60)

Presenter: Louis J. Aronne, M.D., Founder and Director, Center for Weight Management at Weill-Cornell Medical Center

Supporting Materials

 

Investor Contact

Richard Eisenstadt
Chief Financial Officer

Email: reisenstadt@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe